Trial · NCT07900438
A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
NCT07900438, Phase 4, Recruiting, Novo Nordisk A/S
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China. Trials, record NCT07900438. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900438
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
- NCT number
- NCT07900438
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 300 participants, estimated
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Cardiovascular Risk, Chronic Kidney Disease
- Interventions
- Semaglutide
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to first occurrence of a composite endpoint consisting of: Onset of persistent reduction of ≥ 50% in eGFR compared with baseline, Onset of persistent eGFR < 15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death, CV death | From Baseline (Week 0) up to Week 169 | Measured in month(s) |
| Secondary | Change in estimated glomerular filtration rate (eGFR) (creatinine CKDEPI, 2009) | From Baseline (Week 0) up to Week 169 | Measured in milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) |
| Secondary | Change in eGFR (creatinine CKDEPI, 2012) | From Baseline (Week 0) up to Week 169 | Measured in mL/min/1.73 m\^2 |
| Secondary | Change in eGFR (cystatin C-creatinine CKD-EPI, 2021) | From Baseline (Week 0) up to Week 169 | Measured in mL/min/1.73 m\^2 |
| Secondary | Relative change in Urine Albumin-to-Creatinine Ratio (UACR) | From Baseline (Week 0) up to Week 169 | Measured in Percentage (%) |
| Secondary | Time to all-cause death | From Baseline (Week 0) up to Week 169 | Measured in month(s) |
| Secondary | Time to first occurrence of composite MACE endpoint consisting of Non-fatal myocardial infarction, Non-fatal stroke & CV death | From Baseline (Week 0) up to Week 169 | Measured in month(s) |
| Secondary | Change in glycated haemoglobin (HbA1c) | From Baseline (Week 0) up to Week 169 | Measured in percentage point |
| Secondary | Number of serious adverse events | From Baseline (Week 0) up to Week 169 | Measured as events |
| Secondary | Number of severe hypoglycaemic episodes | From Baseline (Week 0) up to Week 169 | Measured as events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900438
GET https://conductscience.org/api/trials/v1/NCT07900438/registered